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Abstract Protease involvement has been implicated in the sig- 
nalling process of activation-induced apoptosis. Here we report 
the isolation of a protease from Jurkat T cells undergoing Fas- 
induced apoptosis. Although the protease probably is a serine 
protease, it seems to be distantly related to members of the 
ICEIced-31Ich-l(nedd-2) family. In a cell-free system using iso- 
lated thymocyte nuclei, the protease rapidly induces DNA frag- 
mentation and morphological changes typically seen in apoptosis. 
Our results clearly show protease activation downstream to Fas- 
ligation and implicate an important role for the isolated protease 
in signalling of Fas-induced apoptosis. 
Ket, words: Apoptosis; Fas/APO-I;  Cell-flee system; Protease 
inhibitor; DNA fragmentation: Interleukin l-fl-converting 
enzyme 
1. Introduction 
Fas (APO-1/CD95) is a member of the tumor necrosis/nerve 
growth factor receptor superfamily and mediates apoptosis in 
various cell types that express the Fas receptor. Mice carrying 
mutations in the Fas ligand (gld mice) or the Fas receptor (lpr 
mice) display a nonfunctional Fas ligand/Fas receptor pair and 
suffer from autoimmune diseases. The effects of these loss-of- 
function mutations indicate that the Fas-system plays an im- 
portant role in the processes involved in T cell development (see 
[1] for recent review). 
It has recently been shown that T cell receptor stimulation 
induces the expression of both Fas and its ligand on T cells, and 
that activation-induced apoptosis can be inhibited by blocking 
either the receptor or the ligand [2-4]. Despite the rapidly grow- 
ing interest in Fas-induced apoptosis, very little is known about 
the molecular mechanism involved in its induction of apoptosis. 
We have shown that several protease inhibitors can block 
Fas-induced apoptosis in Jurkat T cells (Weis, M., Schlegel, J., 
Kass, G.E.N., Holmst6m, T.H., Peters, I., Eriksson, J., Or- 
renius, S. and Chow, S.E. (1995) manuscript submitted). The 
involvement of proteases has also been implicated in the induc- 
tion of apoptosis in other systems [5 11]. In a cell-free system 
adapted from [12] using extracts from Jurkat T cells undergoing 
Fas-induced apoptosis, a proteolytic activity inducing DNA 
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fragmentation and morphological changes typical of apoptosis 
was detected (Chow, S.C., Weis, M., Kass, G.E.N., Holm- 
str6m, T.H., Eriksson, J. and Orrenius, S. (1995) Manuscript 
submitted). We now describe the partial purification and char- 
acterization of this protease. Inhibitor studies with a variety of 
protease inhibitors reveal that the protease is probably a serinc 
protease with some similarities to members of the ICE/ced-3/ 
lch-1 (nedd-2) protease family. The importance of these findings 
in signalling of Fas-induced apoptosis is discussed. 
2. Materials and methods 
2.1. Reagents 
Anti-human Eas antibody (IgM, clone CH-II) was purchased from 
AMS Biotechnology, Sweden. PSI was a gift from S. Wilk, Mount Sinai 
School of Medicine, New York, USA. DCI was obtained from Calbio- 
chem, Pefabloc from Boehringer-Mannheim, TLCK and TPCK from 
SIGMA, and VAD-FK from Enzyme Systems (Dublin, USA). All 
other chemicals were of research grade and obtained from local sources. 
2.2. Cell culture 
The human leukemic T cell line, Jurkat, was obtained from ATCC 
(Maryland, USA) and grown according to ATCC guidelines. 
2.3. Isolation of the Jurkat protease involved & Fas-induced apoptosis 
Jurkat cells (15 x ll) ~ cells/ml) were incubated at 37°C with anti-Fas 
antibody (750 ng/ml) in medium. After 75 to 90 rain, when at least 60% 
of the cells showed typical apoptotic features as assessed by light mi- 
croscopy, the cells were centrifuged, washed once with ice-cold medium 
and resuspended in S-buffer consisting of 50 mM NaC1, 2 mM MgCI~, 
40 mM fl-glycerophosphate, 5 mM EGTA, 10 mM HEPES, pH 7.0 (500 
/zl per 300 x 106 cells). After four cycles of freezing and thawing, the cell 
lysates were centrifuged for 15 min at 20,000 x g lo pellet the membra- 
nous fraction. The supernatant was then centrifuged a further 30 rain 
at 120,000 x g to obtain a supernatant fraction consisting mainly of 
cytosolic proteins. 
For the isolation of the Jurkat protease a three-step chromatograph- 
ical procedure was used. In brief, a gel filtration step on a SUPEROSE 
12 HR 10/30 FPLC column (Pharmacia) to remove protein aggregates 
and low molecular weight contaminants was tk~llowed by an affinity 
chromatography step on a 5 ml HiTrap Blue column (Pharmacia). 
eluting bound proteins with a salt gradient from 0.05 to 1 M NaCh The 
final isolation was on an anion exchange column (Mono Q HR 5/5. 
Pharmacia) with the protease activity eluting at /50 mM NaC1. 
2.4. Isolation of nuclei and incubation eondition.~ 
Rat thymocyte nuclei were prepared as described [13] with two minor 
modifications: (i) before cell homogenization, the nuclei bnffer was 
supplemented with 0.02% NP-40 and (ii) DTT and PMSF were not 
added. Using a recently published in vitro system [12] with a minor 
modification (no DTT present), isolated nuclei were incubated at 37°C 
with the different fractions containing the Jurkat protease in S-buffer. 
The total assay volume was normally 60 pl, consisting of 20 40 pl of 
the fraction containing the Jurkat protease (dialysed against S-buffer). 
15 20 x 106 nuclei, and an ATP regenerating system [12]. After 60 to 
80 min the reaction was stopped and the samples divided for analysis 
by CSOM, FIGE and conventional garose lectrophoresis (see belowl. 
2.5. Analysis qf oligonucleosomal and HM W DNA Jkagment.~ 
Analysis of oligonucleosomal DNA fragmenls was done with a 
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10/ll aliquot of the terminated incubation using an agarose gel electro- 
phoresis method escribed by Sorenson et al. [14]. After the run, the 
gel was tained with ethidium bromide, visualized using a 305 nm UV 
light source, and photographed using Polaroid 665 film. Boehringer 
Mannheim DNA Marker VI was used as a marker. The formation of 
HMW DNA fragments was analyzed using a 30/11 aliquot of the 
terminated incubation by FIGE as described in [15], with minor modi- 
fications: (i) instead of the whole agarose plugs, 1 mm slices of the plugs 
were used, and (ii) a vertical gel chamber was used in combination with 
a switcher program adapted for vertical gels. DNA was stained and 
visualized as described above. DNA marker for FIGE (0.1 200 kbp) 
was purchased from Sigma. 
2.6. Assessment of nuclear morphology b  CSOM 
To monitor changes in nuclear morphology, l0/~l aliquots of the 
terminated incubation were incubated with propidium iodide (100/lg/ 
ml) on ice for 2 rain before viewing using a Bio-Rad MRC-600 laser 
confocal microscope with BHS filter (Bio-Rad). 
3. Results 
3.1. The supernatant of the cell lysate of anti-Fas treated Jurkat 
cells contains an ctivity leading to apoptotic hanges in 
isolated nuclei 
CSOM analysis howed that incubation of isolated rat thy- 
mocyte nuclei with the supernatant of the cell lysate prepared 
from anti-Fas treated Jurkat cells (Fas-extract) led to changes 
in nuclear morphology typically seen in apoptosis [16] (compare 
Fig. 1A,B). Incubation of the nuclei with supernatant prepared 
from untreated Jurkat cells did not cause these changes, thus 
indicating that the activity promoting the formation of apop- 
totic nuclei was only present in anti-Fas treated cells. Analysis 
of the DNA by F IGE (Fig. 1C) and conventional garose gel 
electrophoresis (Fig. 1D) showed the formation of HMW and 
oligonucleosomal DNA fragments in the nuclei ncubated with 
Fas-extract (Fig. 1C,D, lane 3). Neither incubation of the nuclei 
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alone (Fig. 1C,D, lane 1), nor incubation of the nuclei in the 
presence of extract prepared from untreated Jurkat cells (Fig. 
IC,D, lane 2) led to DNA fragmentation. Furthermore, anti- 
Fas antibody did not cause apoptotic hanges when incubated 
directly with thymocyte nuclei (not shown). Incubation of nu- 
clei from untreated Jurkat cells with Fas-extract led to similar 
changes in nuclear morphology and chromatin structure as 
seen with thymocyte nuclei (not shown). 
3.2. The activity causing apoptotic hanges in isolated thymocyte 
nuclei is a protease 
In order to characterize the activity causing apoptotic nuclei, 
we have attempted to purify the supernatant obtained from the 
cell lysate of anti-Fas treated Jurkat cells (Fas-extract). Gel 
filtration chromatography of the Fas-extract on a SUPEROSE 
12 HR 10130 FPLC column calibrated with the marker proteins 
supplied by Pharmacia revealed that the fractions correspond- 
ing to a mol.wt, of 95 + 15 kDa (mean + S.D., n = 5) had the 
highest activity (not shown). The eluted protein was further 
purified by affinity chromatography and anion exchange 
chromatography asdescribed in section 2. Comparison of this 
partially purified protein with the starting material showed that 
(i) the isolated protein still had the activity to induce apoptotic 
changes in nuclear morphology (Table 1 ) and DNA fragmenta- 
tion (Fig. 2), and that (ii) the three-step chromatographical 
procedure resulted in a 66-fold enrichment of activity in the 
isolated protein as compared to the Fas-extract (Table 1). The 
partially purified protein fraction did not induce apoptosis 
when applied to intact Jurkat cells (not shown), implying that 
it acts on an intracellular target. 
The isolated protein was further characterized by incubating 
it with thymocyte nuclei in the presence of inhibitors of differ- 
ent classes of proteases. The results obtained showed that 
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Fig. 1. Induction of apoptotic-like changes in isolated rat thymocyte nuclei by the supernatant of the cell lysate from anti-Fas treated Jurkat cells 
(Fas-extract). (A) and (B) are CSOM pictures showing the morphology of untreated nuclei and nuclei treated with Fas-extract, respectively. The scale 
bar corresponds to 5 pm. (C) HMW and (D) oligonucleosomal DNA fragmentation: nuclei n the absence of any extract (control, lane 1), nuclei 
in the presence of extract from untreated Jurkat cells (lane 2), and in the presence of Fas-extract (lane 3). M = Marker. 
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Fig. 2. (A) HMW and (B) oligonucleosomal DNA fragmentation in isolated thymocyte nuclei induced by the partially purified Jurkat protease and 
its inhibition by various agents. Jurkat protease pretreated with various agents (see below) for 30 min at room temperature and dialyzed against 
S-buffer was incubated with thymocyte nuclei for 70 rain as described in section 2. (1) DMSO (vehicle, control), (2) 100,uM TPCK, (3) 200/2M TLCK, 
(4) 100 ,uM DCI, (5) 25/,tM VAD-FK, (6) 250 uM iodoacetic acid. M = Marker. 
several inhibitors acting preferentially on serine (but in part 
also on cysteine) proteases were effective (Fig. 2), while specific 
inhibitors of cysteine proteases and of the chymotryptic-like 
activity of the 20 S proteasome were ineffective (Table 2). 
The agents used in Fig. 2 are known to irreversibly inhibit 
preferentially serine (TPCK, TLCK, DCI) or cysteine proteases 
(iodoacetic acid and VAD-FK). Therefore, the partially puri- 
fied protein was treated with the different inhibitors (or the 
solvent) and then dialyzed against S-buffer before incubation 
with thymocyte nuclei, thereby avoiding the presence of inhib- 
itors during incubation of the isolated protein with the nuclei. 
This allowed us to determine whether the inhibitors indeed 
acted on the isolated protein and not by blocking a later step 
involved in nuclear fragmentation. Fig. 2 shows that the 
dialyzed partially purified protein retained the activity to in- 
duce the formation of apoptotic nuclei, i.e. it induced HMW 
(Fig. 2A) and oligonucleosomal (Fig. 2B) DNA fragmentation 
in thymocyte nuclei (lane 1), whereas pretreatment of the 
isolated protein with TPCK, TLCK, DCI, VAD-FK, or 
iodoacetic acid (lanes 2 6) prior to dialysis irreversibly inhib- 
ited its activity. These r sults trongly suggest that the partially 
purified protein is a protease. In support of this we have also 
found that the partially purified protease has no endonuclease 
activity when incubated with A-DNA under standard condi- 
tions (not shown). 
Since loading different ypes of cells with the proteases tryp- 
sin and chymotrypsin has been shown to cause apoptotic ell 
death [11], we investigated if these nonspecific serine proteases 
could mimic the activity of the 'Jurkat protease' on isolated 
nuclei. Isolated thymocyte nuclei were therefore incubated 
under standard conditions with trypsin and chymotrypsin (final 
concentration ranging from 85 ng/ml to 0.85 mg/ml). Both 
proteases were found to digest the nuclei (mainly at the higher 
concentrations), but DNA fragmentation and apoptosis-like 
changes in nuclear morphology could not be detected (not 
shown). 
Table l 
Comparison of the supernatant obtained from the cell lysate of anti-Fas 
treated Jurkat cells (Fas-extract) with the partially purified protein 
isolated from the Fas-extract 
Protein Activity ~' Factor of 
concentration purification 
Fas extract 22.6 mg/ml 59 AU/mg l 
Partially purified protein 57/2g/ml 3,900 AU/mg 66 
Protein concentration and activity measurements of a typical isolation 
are shown. The isolation described in section 2 has been repeated three 
times with similar results. 
"1 AU (arbitrary unit) corresponds tothe amount of protein eeded to 
lead to apoptotic changes in the morphology of> 50% of the nuclei after 
one hour, as judged by CSOM. 
4. Discussion 
4.1. The involvement of  proteases in Fas-induced apoptosis 
We have described the isolation and partial chracterization 
of a protease from Jurkat cells undergoing apoptosis after treat- 
ment with anti-Fas antibody. Using a cell-free system adapted 
from Lazebnik et al. [12] we found that incubation of rat thy- 
mocyte nuclei with supernatants obtained from lysates of anti- 
Fas treated Jurkat cells resulted in nuclear changes typically 
seen in apoptosis, i.e. chromatin condensation and abutting 
towards the nuclear membrane, and fragmentation f the DNA 
into HMW and oligonucleosomal fragments. Extracts from 
untreated Jurkat cells obtained by the same procedure did not 
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show this activity. The activity leading to apoptotic nuclei had 
no endonuclease activity but was blocked by a variety of pro- 
tease inhibitors. Therefore, these results provide strong evi- 
dence for the involvement of proteolysis in Fas-induced apop- 
tosis. 
4.2. The protease involved in Fas-induced apoptosis in Jurkat 
cells is a novel protease distantly related to ICE 
To characterize the ' Jurkat protease' it was necessary to first 
remove low molecular weight contaminants and as many other 
proteins as possible. Therefore, we enriched the Fas-extract 
more than 60-fold using a three-step chromatographical proce- 
dure. SDS-polyacrylamide g l electrophoresis analysis of this 
partially purified protease fraction revealed 6 bands by silver 
staining (not shown). We have not been able to determine 
which band corresponds to the protease activity. Therefore, 
work is underway to establish a sensitive assay for protease 
activity measurement that would allow purification of the pro- 
tease to homogeneity. 
Leupeptin and E64, two well-known cysteine protease inhib- 
itors, did not affect the ' Jurkat protease'. The same held true 
for inhibitors of calpains as well as for a novel inhibitor of the 
chymotrypsin-like activity of the proteasome. However, incu- 
bation of the 'Jurkat protease' with iodoacetic acid led to its 
irreversible inhibition. The inhibition pattern obtained corre- 
sponds to the inhibitor profile originally published for ICE [18]. 
The observation that the ' Jurkat protease' has similarities with 
ICE is further supported by the finding that it was irreversibly 
inhibited by VAD-FK, a specific inhibitor for ICE. However, 
the isolated protease was also inhibited by TPCK, TLCK and 
DCI, agents belonging to two different classes of protease in- 
hibitors acting preferentially on serine proteases, while ICE is 
most probably a cysteine protease. Furthermore, Pefabloc, a 
member of a third class of serine protease inhibitors, also 
showed partial inhibition of the ' Jurkat protease' at high con- 
centrations (2 raM, not shown). These results suggest hat the 
' Jurkat protease' is a serine protease and distinct from ICE, 
although it is important o remember the difficulty of distin- 
guishing cysteine and serine proteases only on the basis of 
inhibitor studies. In this context it is worth noting that the 
amino acid sequence of crmA, a specific inhibitor of ICE [8], 
is homologous to that of members of the serpin superfamily 
which usually inhibit serine proteases by acting as pseudosub- 
strates ([19] and references therein), providing further evidence 
Table 2 
Agents that failed to inhibit HMW and oligonucleosomal DNA frag- 
mentation mediated by the isolated Jurkat protease 
Addition ~' Concentration range 
tested 
Inhibitors of Cystein Proteases 
Leupeptin b 10- 50/aM 
E64 c 10 50/aM 
N-Acetyl-Leu-Leu-norleucinal d 5-50/aM 
N-Acetyl-Leu-Leu-methional a 5 50/aM 
Inhibitor of the 20 S proteasome e 
PSI d 5 100/aM 
~' Thymocyte nuclei were incubated with the isolated Jurkat protease in 
the presence of the different inhibitors as described in section 2. The 
agents were prepared as 200 times stock solutions in water b, 50% etha- 
nol in water c or DMSO d. eSpecific inhibitor of the chymotryptic-like 
activity of the proteasome [17]. 
for possible cross-reactivities between inhibitors of serine and 
cysteine proteases. 
The two serine proteases trypsin and chymotrypsin, recently 
shown to induce apoptotic ell death when loaded into different 
types of cells [11], failed to induce any apoptotic changes in 
isolated thymocyte nuclei in the cell-free system described here. 
This provides strong evidence for the necessity of a specific 
proteolytic step for the induction of the nuclear changes seen 
in Fas-induced apoptosis. 
In summary, our results show the involvement of the ' Jurkat 
protease' in Fas-induced apoptosis. This enzyme differs in size 
and inhibition pattern from other proteases implicated in apop- 
tosis, such as Granzyme [20], 24 kDa U937 protease [10], 
CPP32 [21], ICE [18], and pr iCE [9]. It is therefore most prob- 
ably a novel protease, that, as judged by its inhibition profile, 
is distantly related to ICE. 
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